Clovis High Plains is a medicare approved dialysis facility center in Clovis, New Mexico and it has 15 dialysis stations. It is located in Curry county at 121 Townsgate Plaza, Clovis, NM, 88101. You can reach out to the office of Clovis High Plains at (575) 763-2216. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Clovis High Plains has the following ownership type - Profit. It was first certified by medicare in April, 2017. The medicare id for this facility is 322553 and it accepts patients under medicare ESRD program.
| Name | Clovis High Plains |
|---|---|
| Location | 121 Townsgate Plaza, Clovis, New Mexico |
| No. of Dialysis Stations | 15 |
| Medicare ID | 322553 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 121 Townsgate Plaza, Clovis, New Mexico, 88101 | |
| (575) 763-2216 | |
| Not Available |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago
| NPI Number | 1215384458 |
| Organization Name | Fresenius Kidney Care Clovis High Plains |
| Doing Business As | Bio-medical Applications Of New Mexico, Inc. |
| Address | 121 Townsgate Plz Clovis, New Mexico, 88101 |
| Phone Number | (575) 763-2216 |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 11 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 9 |
| Medicare patients who had average hemoglobin (hgb) greater than 12 g/dL | 9 |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 23 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 108 |
| Percentage of adult patients getting regular hemodialysis at the center | 87 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 7 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 33 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Clovis High Plains with elevated calcium levels.
| Patients with hypercalcemia | 30 |
| Hypercalcemia patient months | 142 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 31 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 16 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 25 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 20 |
| Patient months included in arterial venous fistula and catheter summaries | 97 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 56 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 16 |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
The House Appropriations Committee on Tuesday released the FY12 Foreign Relations Authorization Act "that slashes State Department funding and foreign aid," The Hill's "On The Money" blog reports.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced top-line results from a Category 3 human abuse liability (HAL) study of Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product candidate in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy.
In a post in the State Department's "DipNote" blog, Krysten Carrera, a Presidential Management fellow at the National Cancer Institute currently serving in the Bureau of International Organization Affairs, discusses "the growing international effort to address the threat of chronic non-communicable diseases."
› Verified 4 days ago